J. Goldman & CO LP Tg Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 8,036 shares of TGTX stock, worth $269,929. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,036
Previous 8,036
-0.0%
Holding current value
$269,929
Previous $241,000
31.12%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding TGTX
# of Institutions
415Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$524 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$383 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$250 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$110 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$95.6 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.88B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...